Company intelligence
Caris Life Sciences
Fulfilling the promise of precision medicine through quality and innovation.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets.
Verified activity
Signals from Caris Life Sciences
14 published signals
Products & Services
Caris Life Sciences launched Caris Detect™, an AI-powered platform using whole-genome and transcriptome analysis trained on over 50 billion molecular markers from over 1 million patient cases to detect cancer signals in blood.
Reported by Caris Life Sciences
Products & Services
Caris Life Sciences launched a new national campaign titled Math featuring Kevin Costner as the actor, producer, and director.
Reported by Caris Life Sciences
People
Caris Life Sciences hired Anthony Angley as an MI Clarity Account Executive.
Reported by Anthony Angley
Products & Services
Caris Life Sciences launched a new national commercial featuring Kevin Costner for Caris Detect, a multi-cancer early detection blood test designed to identify cancer-associated signals in the bloodstream.
Reported by Narendra Chokshi
Presence & Recognition
Caris Life Sciences announced that it will host the 2026 Michelin Global Innovation Awards.
Reported by Chase G. Wasson
Research & Knowledge
Caris Life Sciences developed Caris MI Clarity™, a new approach to prognostic assessment in early-stage breast cancer trained and validated on TAILORx and NSABP B-42 clinical trial data, delivering independent risk insights across 15 years from a single diagnostic sample.
Reported by Caris Life Sciences
Presence & Recognition
Caris Life Sciences will host a fundraiser and screening of the movie release
Reported by Janet Waldron
Products & Services
Caris Life Sciences introduced Caris Detect, a multi-cancer early detection blood test combining ultra-deep whole genome and whole transcriptome sequencing with advanced AI trained on over 1 million patient cases and 50 billion molecular markers.
Reported by Caris Life Sciences
Products & Services
Caris Life Sciences launched Caris ChromoSeq, a high-coverage Whole Genome Sequencing WGS assay that consolidates cytogenetics, FISH, and targeted next-generation sequencing into a single assay.
Reported by Caris Life Sciences
Presence & Recognition
Caris Life Sciences researchers and the Caris Precision Oncology Alliance will present seven studies at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea.
Reported by Caris Life Sciences
People
Caris Life Sciences is hiring an ABMGG-boarded Technical Director for the laboratory genetics team at the state-of-the-art liquid profiling laboratory in Phoenix, Arizona.
Reported by Bryan Krock, PhD, FACMG
Products & Services
Caris Life Sciences is helping prostate cancer patients through innovative molecular profiling technologies.
Reported by Caris Life Sciences
Products & Services
Caris Life Sciences launched Caris Detect™, a multi-cancer early detection test designed to analyze DNA and RNA and leverage AI trained on oncology datasets.
Reported by Caris Life Sciences
Products & Services
Caris Life Sciences launched MI Cancer Seek, the first and only simultaneous Whole Exome Sequencing and Whole Transcriptome Sequencing based assay with FDA-approved CDx indications, designed for adult and pediatric patients aged 1+
Reported by Caris Life Sciences